Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2regorafenib 1envafolimab 1P7170 compound 1N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Refractory Solid Tumors × Immune Checkpoint Inhibitors × Clear all
NCT07327411 2026-01-08

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Second Affiliated Hospital of Soochow University

Phase 2 Not yet recruiting
40 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡